LUND (SWEDEN) - Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced that its abstract on the CLARITI and VERIFI validation studies for the PancreaSure test has been accepted for an oral plenary presentation at the prestigious American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting in Phoenix, Arizona.

The abstract will be presented today, October 27th, 2025, by Dr. Patricio M Polanco, Professor in the Division of Surgical Oncology and co-director of the Pancreatic Cancer Program and the Pancreatic Cancer Prevention Clinic at the University of Texas Southwestern Medical Center.

The abstract, titled “High Performance of a Blood-Based Biomarker Test to Detect Early-Stage Pancreatic Cancer in a High-Risk Population, Across Two Independent Clinical Validation Studies", was selected by peer reviewers for a prominent plenary presentation. It was also designated as a “newsworthy” abstract to be shared with media members attending the 2025 ACG Annual Scientific Meeting.

“I am pleased to be presenting data showing the consistent and strong performance of PancreaSure in detecting early-stage pancreatic cancer in patients at high risk across two independent clinical studies,” said Dr Patricio M Polanco. “Having effective tools for the early detection of pancreatic cancer is key to impacting patient outcomes in this disease.”

The abstract is based on combined data from Immunovia’s two primary clinical validation studies, CLARITI and VERIFI. The studies confirmed the accuracy of the test for early-stage detection, with a sensitivity of 78% and specificity of 92% in detecting Stage 1 and Stage 2 pancreatic cancer across over 1400 patients.

ACG’s Annual Scientific Meeting & Postgraduate Course is taking place October 24–29, 2025 in Phoenix, Arizona. It brings together clinicians, academicians, researchers, trainees, advanced practice providers, and other professionals in the field of gastrointestinal medicine. The meeting offers in-depth discussions, presentations, exhibits, education, and networking opportunities.

For further information, please contact
Jeff Borcherding, CEO
jeff.borcherding@immunovia.com

Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.

USA is the world’s largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm.
For more information, please visit www.immunovia.com.

Attachments
PancreaSure clinical validation data to be presented at the American Gastroenterology Annual Scientific Meeting

Läs mer på MFN